Run-ZeLi | Oncology | Young Scientsit Award

Posted on by sciencefather

prof. Run-ZeLi | Oncology | Young Scientist  Award 🏆


PI of The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,China🎓

Dr. Run-Ze Li has made substantial contributions to integrative medicine and oncology research, specializing in innovative antitumor therapies. His research focuses on utilizing immune metabolism as a pathway for early diagnosis and targeted treatment of lung cancer. Over the past few years, Dr. Li has led several significant projects (national, provincial, and municipal levels) and published extensively, with 37 SCI-indexed journal papers, including contributions to Nature Communications and other high-impact journals. He has also been recognized with prestigious awards and holds several editorial positions, underscoring his leadership in the field.

 

Professional Profile 

Education 🎓:

🎓 Dr. Li received his Doctorate from the Macau University of Science and Technology, where he developed a foundation in Traditional Chinese Medicine (TCM) and integrative healthcare. This education has guided his innovative approaches to integrating traditional Chinese and Western medicine in antitumor drug research.

Work Experience 💼:

🔬 Over the last few years, Dr. Li has overseen multiple high-impact research projects, including three national, four provincial, and two municipal projects. His extensive research has contributed significantly to clinical advancements in oncology, including his work on antitumor drug development, specifically focused on immune metabolism and biomarker discovery.

Skills 🔍

Innovative Cancer Researcher | Project Leadership | Data Analysis & AI-Driven Biomarker Discovery | Scientific Publication and Editing
Dr. Li’s expertise lies in the application of artificial intelligence for biomarker identification, immune metabolism in oncology, and development of clinical models for lung cancer.

Awards and Honors 🏆

🏆 Dr. Li has earned multiple accolades, including the Excellent Graduate Supervisor Award from Guangzhou University of Chinese Medicine, in recognition of his mentorship and research contributions. He has also published in high-impact journals like Nature Communications, with a total of 37 SCI-indexed publications and 342 citations.

🤝 Memberships:

👥 Dr. Li holds editorial positions as Section Editor for Heliyon-Cancer Research and Associate Editor for Ageing and Cancer Research & Treatment, among other roles. He is also a member of the Youth Editorial Board of Engineering, reflecting his leadership in the field.

Teaching Experience 👩‍🏫:

📚 Dr. Li actively mentors graduate students and oversees TCM-integrated research projects, providing guidance in the intersection of clinical applications and innovative drug research. He is known for his dedication to shaping the next generation of TCM researchers.

 

Research Focus 🔬:

🔍 Dr. Li’s primary research direction centers on integrative medicine for antitumor drug development, particularly targeting immune metabolism for lung cancer diagnosis and treatment. His team has developed a pioneering in vivo model to study immune responses in lung cancer, opening pathways for new therapeutic strategies and targeted drug interventions.

Conclusion 

Dr. Run-Ze Li is a strong candidate for the Young Scientist Award, with a proven track record of innovation, high-impact publications, and leadership within the field of oncology and integrative medicine. His focus on cutting-edge research and a commitment to advancing both scientific understanding and clinical applications makes him an excellent fit for recognition through this award. While he may benefit from expanded research applications and industry collaborations, his current achievements make him exceptionally deserving of this honor.

📚 Publilcation 

  • “Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice”
    • Year: 2024
    • Journal: Frontiers in Immunology
    • Authors: Ma, G., Xu, Z., Li, C., Li, R., Liu, L.
  • “Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment”
    • Year: 2024
    • Journal: Journal of Advanced Research
    • Authors: Liang, T.-L., Pan, H.-D., Yan, P.-Y., Liu, L., Li, R.-Z.
  • “Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy”
    • Year: 2023
    • Journal: Nature Communications
    • Authors: Leung, E.L.-H., Li, R.-Z., Fan, X.-X., Cao, Y., Liu, L.
  • Erratum: “Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice”
    • Year: 2023
    • Journal: Acta Pharmaceutica Sinica B
    • Authors: Fan, X., Mai, C., Zuo, L., Xie, Y., Lai-Han Leung, E.
  • “CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8+Tim3+ exhausted T cells in non-small cell lung cancer”
    • Year: 2023
    • Journal: Pharmacological Research
    • Authors: Wang, J., Li, R.-Z., Wang, W.-J., He, J.-X., Leung, E.L.-H.
  • “Myricetin possesses the potency against SARS-CoV-2 infection through blocking viral-entry facilitators and suppressing inflammation in rats and mice”
    • Year: 2023
    • Journal: Phytomedicine
    • Authors: Pan, H., He, J., Yang, Z., Li, R.-Z., Liu, L.
  • “Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway”
    • Year: 2023
    • Journal: Phytomedicine
    • Authors: Li, R.Z., Guan, X.X., Wang, X.R., Pan, H.-D., Liu, L.
  • “The longitudinal and regional analysis of bleomycin-induced pulmonary fibrosis in mice by microcomputed tomography”
    • Year: 2023
    • Journal: Heliyon
    • Authors: Lai, R., Zhao, C., Guo, W., Liu, L., Pan, H.
  • “Combinational study with network pharmacology, molecular docking and preliminary experiments on exploring common mechanisms underlying the effects of weijing decoction on various pulmonary diseases”
    • Year: 2023
    • Journal: Heliyon
    • Authors: Li, J.-X., Han, Z.-X., Cheng, X., Tang, L., Yang, J.-S.
  • “Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice”
    • Year: 2023
    • Journal: Acta Pharmaceutica Sinica B
    • Authors: Fan, X., Mai, C., Zuo, L., Xie, Y., Leung, E.L.-H.

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award

Posted on by sciencefather

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award🏆


Assistant Professor at Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
🎓

Joanna Jazowiecka-Rakus is an Assistant Professor with a strong focus on advancing cancer research through innovative oncolytic therapies. Her work at the Maria Skłodowska Memorial National Institute of Oncology in Gliwice, Poland, positions her as a leading expert in experimental cancer treatments. Dr. Jazowiecka-Rakus’s pioneering research in oncolytic virotherapy and nanocarrier drug delivery aims to address complex cancers like pancreatic adenocarcinoma, glioma, and melanoma. With a reputation for pushing boundaries in cancer treatment, she continues to make strides in developing therapies that offer new hope for patients with challenging diagnoses.

Professional Profile 

🎓 Education

Dr. Jazowiecka-Rakus holds a Master of Science in Biology from the Faculty of Biology, University of Silesia, Katowice, Poland (2001), followed by a Ph.D. in Medical Biology from the National Institute of Oncology, Warsaw, Poland (2007). In recognition of her exceptional contributions to cancer research, she earned a D.Sc. (habilitation) in Medical Sciences from the same institution. Her academic path reflects her dedication to enhancing cancer treatment through rigorous scientific training and specialization.

🏢 Work Experience

Throughout her career, Dr. Jazowiecka-Rakus has held esteemed research positions, including her current role as an Assistant Professor at the National Institute of Oncology. Her work has been instrumental in projects funded by prestigious institutions like the International Center for Genetic Engineering and Biotechnology and the National Science Center of Poland. Notably, her research covers a wide spectrum of experimental cancer therapies, including the use of myxoma viruses and mesenchymal stem cells to treat melanoma, ovarian cancer, and glioma. She has also forged valuable collaborations with global institutions, such as the Biodesign Institute at the University of Arizona, Tempe, USA.

🧬 Skills

Dr. Jazowiecka-Rakus brings a wealth of expertise in cancer treatment, highlighted by her skills in oncolytic virotherapy, cancer immunotherapy, and advanced drug delivery systems. Her work with oncolytic virotherapy focuses on developing viral therapies that specifically target and destroy cancer cells, offering a promising alternative to traditional cancer treatments. In cancer immunotherapy, she integrates immune-enhancing agents to create therapies for advanced cancers. Her pioneering methods for stem cell-based drug delivery use mesenchymal stem cells as carriers for oncolytic viruses, targeting tumor cells more effectively. Additionally, she has developed nanocarrier drug formulations that improve the delivery and efficacy of drugs in cancer treatment.

Awards and Honors 🏆

Dr. Jazowiecka-Rakus’s dedication to cancer research has earned her numerous accolades. Between 2017 and 2020, she was awarded a research grant by the International Center for Genetic Engineering and Biotechnology to study oncolytic melanoma therapy, underlining her impact in this vital area. Her scholarly contributions include 18 articles published in high-impact journals indexed in Web of Science and Scopus, reflecting her influence and recognition within the cancer research community. Her works have accumulated a citation index of over 431, showcasing the significant reach and impact of her research.

🌐 Memberships

Active in professional societies, Dr. Jazowiecka-Rakus is an auditor for the Association for the Support of Cancer Research in Gliwice, Poland, where she contributes to promoting research integrity and supporting advancements in cancer studies. She is also a member of the Polish Radiation Research Society based in Warsaw, where she engages with other professionals dedicated to improving cancer treatment and sharing knowledge within the field.

📚 Teaching Experience

As an Assistant Professor, Dr. Jazowiecka-Rakus is committed to educating and mentoring the next generation of cancer researchers at the National Institute of Oncology. Her teaching covers essential aspects of oncology and medical biology, with a particular focus on innovative treatment strategies in cancer research. Through her courses and mentoring, she guides students in understanding the complexities of cancer treatment, encouraging them to pursue research that makes a real-world impact.

🔬 Research Focus

Dr. Jazowiecka-Rakus’s research centers on developing experimental therapies for aggressive cancers. Her work includes the creation of oncolytic myxoma virus constructs, which use mesenchymal stem cells as carriers to deliver viral therapies specifically targeting cancers such as pancreatic adenocarcinoma and glioma. She has developed advanced blood-brain barrier crossing techniques to treat glioma through intra-arterial delivery, offering a new method to target brain tumors effectively. Additionally, her research on 3D models for cancer uses spheroid and organoid models to test therapies for disseminated ovarian cancer, pushing the boundaries of cancer treatment with innovative laboratory models that mimic real-world conditions. Dr. Jazowiecka-Rakus’s interdisciplinary approach highlights her dedication to advancing the field of cancer therapy and improving patient outcomes.

Conclusion 

In conclusion, Dr. Joanna Jazowiecka-Rakus exemplifies the qualities of an outstanding researcher through her innovative projects, significant contributions to cancer research, and a strong academic foundation. Her ongoing work and potential for future advancements make her a deserving candidate for the Best Researcher Award. Enhancing her publication record and pursuing patent opportunities would further solidify her standing as a leader in the field.

📚 Publilcation 

  • Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood–Brain Barrier and Treat Murine Glioma
  • Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
  • Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
  • Removal of Heavy Metal Ions from Wastewaters: An Application of Sodium Trithiocarbonate and Wastewater Toxicity Assessment
  • COVID-19 Autopsies: A Case Series from Poland
  • Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
  • Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses